Testing New Drug Combinations After Liver Cancer Surgery

This real-world study is testing whether adding adebrelimab — an immunotherapy drug — to three different chemotherapy or targeted therapy combinations can help prevent intrahepatic cholangiocarcinoma (a type of liver cancer) from coming back after surgery. The study will compare these new treatment approaches against the standard care that patients have received in the past. Researchers hope to find the most effective way to treat patients whose tumors have features that make them more likely to recur.

After surgery, patients with high-risk liver cancer have a significant chance that cancer will return. Doctors want to find better medications given after surgery to reduce this risk, and this study explores whether combining immunotherapy with existing treatments might work better than chemotherapy alone.